Felipe M. Heiderich

• Ouro Medicines in its acquisition by Gilead Sciences for up to $2.375 billion
• Orna Therapeutics in its acquisition by Eli Lilly & Company for up to $2.4 billion
• Moderna’s acquisition of OriCiro Geonomics K.K., a Japanese synthetic DNA company*
• Moderna’s acquisition of FDA Priority Review Vouchers from various sellers* 
• Johnson & Johnson Consumer Inc.’s acquisition of a mobile imaging technology company* 
• Johnson & Johnson Consumer Inc.’s sale of a maternal and baby health digital platform* 
• Johnson & Johnson Consumer Inc.’s sale of its RoC® skincare business to Gryphon Investors* 
• Johnson & Johnson Consumer Inc.’s acquisition of Zarbee’s Naturals, Inc., a maker of pediatric health and wellness products*
• Public technology company in its acquisition of a global online retailer*
• Public technology company in its acquisition of a cybersecurity startup*
• Public media company in the acquisition of Latin American venture-backed technology company*
• Private financial services company in establishing a $2.0 billion joint venture for its strategy and management consulting business*
• Public financial services company in its $11 billion merger and response to an unsolicited interloping offer*
• Public automotive company in a $250 million investment and strategic partnership* 
• Public industrials company is its $6.4 billion acquisition of a public chemical and materials company*
• Various sponsor-backed private technology companies in acquisitions and exits of middle-market software businesses* 

• Quotient Therapeutics in its multi-year research collaboration with Merck to discover novel drug targets in inflammatory bowel disease using Quotient’s somatic genomics platform technology, for up to $2.2 billion
• Moderna on a strategic collaboration with Recordation for $50 million upfront and up to an additional $110 million in near-term development and regulatory milestones
• ProFound Therapeutics on a four-year collaboration with Novartis to discover and develop novel therapeutics for cardiovascular disease leveraging its ProFoundry™ Platform, for an upfront payment of $25 million and up to $750 million in milestone payments
• Moderna’s Research and Development Funding Collaboration with Blackstone Life Sciences*
• Moderna’s Research and Development Collaboration with Immatics N.V.*
• Moderna’s Research and Development Collaboration with CARsgen Therapeutics Holdings Ltd.*
• Moderna’s Research and Development Collaboration with Generation Bio Co.*
• Moderna’s Research and Development Collaboration with LifeEdit Therapeutics, Inc. and ElevateBio, LLC*
• Moderna’s Research and Development Collaboration with CytomX Therapeutics, Inc.*
• Moderna’s Research and Option Agreement with Novozymes, Inc.* 
• Moderna’s Research, Development and Commercialization Collaboration with Carisma Therapeutics, Inc.* 
• Moderna’s Research, Development and Commercialization Collaboration with Metagenomi, Inc.*
• Moderna’s Collaboration and Option Agreement with AbCellera Biologics Inc.*
• Moderna’s Research and Option Agreement with Autolus Therapeutics plc*
• Moderna’s License and Collaboration with Takeda Pharmaceutical Co. Ltd.* 
• Moderna’s Research Collaboration with Chiesi Farmaceutici S.p.A.*
• Moderna’s long-term, multi-billion-dollar Manufacturing, Supply and R&D partnerships with the governments of the UK, Australia and Canada* 

• Forbion and Novartis Ventures as lead investors in Protego Biopharma's $130 million Series B financing
• BeOne Medicines in its sale of royalty rights on the worldwide sales, excluding China, of Amgen’s IMDELLTRA® (tarlatamab-dlle) for up to $950 million to Royalty Pharma
• Moderna’s PIPE investment in Generation Bio Co. in connection with the Collaboration between the companies*
• Moderna’s convertible note investment in Carisma Therapeutics, Inc. and subsequent reverse merger, in connection with the Collaboration between the companies*
• Moderna’s preferred equity investment in Metagenomi, Inc’s Series B financing*
• Various venture-backed technology companies in connection with venture financing rounds led by venture capital funds and strategic investors*  
• Various corporate venture funds in connection with investments in venture-backed businesses* 
• Financial services company in its $3.0 billion IPO and NYSE listing of its common stock*
• Financial services company in its $50 million IPO and NYSE listing of its common stock*

*Denotes experience prior to joining Goodwin